Answers are grounded in this paper and cite their sources.
Retrospective study reveals low BMI and poor performance worsen tolerability to treatment in elderly, indicating need for better assessments.
Low BMI and poor performance status were independently associated with decreased tolerability to anti-PD-L1 antibody combined with platinum-etoposide in elderly patients with ES-SCLC. These findings underscore the importance of incorporating geriatric assessments into treatment decision-making for this population.
No takes yet. Share an insight, caveat, or question.
Terashima et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: